India’s pharma market to be worth $130 billion by 2030
The Indian pharmaceutical market is estimated to be worth $130 billion by 2030 from an estimated US$ 41 billion in 2021, the Economic.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
The Indian pharmaceutical market is estimated to be worth $130 billion by 2030 from an estimated US$ 41 billion in 2021, the Economic.
Syngene's operations in the Indian city of Hyderabad have been transferred to another wholly-armed arm of the company with effect from April 1,.
Lupin, headquartered in Mumbai, India, has received tentative approval from the FDA under the US President’s Emergency Plan for AIDS Relief for its.
Pfizer refuted allegations by Project Veritas, a media organization, in its ongoing COVID-19 vaccine work stating it has “not conducted gain-of-function” or “directed.
Studies on animals have shown that a drug used to treat hypertension prolongs the human lifespan and slows ageing, mimicking the effects of.
COVID-19 will remain a pandemic as it continues to constitute a public health emergency of international concern, the WHO’s highest form of an.
The number of people affected by neglected tropical diseases (NTDs) has fallen by 80 million between 2020 and 2021, a WHO report stated.
PathLabs Unifiers, a subsidiary of diagnostic services company Dr. Lal PathLabs, has acquired a 10% stake in one of its business units, APRL.
Sun Pharmaceuticals announced it had acquired three brands from Aksigen to treat postoperative inflammation in patients undergoing minor surgery and dental procedures.
Dr. Reddy's unveiled its difluprednate ophthalmic emulsion in the US market for treating inflammation and pain associated with eye surgery.